In a phase 3 placebo-controlled trial in people with or at risk of frontotemporal dementia due to GRN mutations, intravenous latozinemab every 4 weeks for 96 weeks raised plasma and CSF progranulin but did not slow clinical or biomarker progression. No adverse safety signals.
RCT
Simmons et al. Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations